Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration of momelotinib may decrease the plasma concentrations and effects of drugs that are substrates of CYP450 1A2. The proposed mechanism, based on in vitro data, is increased drug clearance due to momelotinib-mediated induction of the CYP450 1A2 isoenzyme. However, clinical data are not available.

MANAGEMENT: Caution is recommended with the concomitant use of momelotinib and CYP450 1A2 substrates, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever momelotinib is added to or withdrawn from therapy with these drugs. Individual product labeling for the coadministered drug may also be consulted for specific guidance.

Pirfenidone should be taken with food to help reduce dizziness and gastrointestinal side effects such as diarrhea, nausea, vomiting, and upset stomach. Avoid smoking during treatment, as cigarette smoking can reduce the blood levels and effects of pirfenidone. If you are a smoker, you should try to quit smoking before starting treatment. Talk to your doctor or pharmacist if you have any questions or concerns, or need help in finding a smoking cessation program. You should also avoid consuming grapefruit or grapefruit juice while taking pirfenidone, as it may increase blood levels of the medication and lead to more side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.